Veillon Romain, Shabushnig John, Aabye-Hansen Lars, Duvinage Matthieu, Eckstein Christian, Li Zheng, Sardella Andrea, Soto Manuel, Torres Jorge Delgado, Turnquist Brian
GSK, Wavres, Belgium.
Insight Pharma Consulting, LLC, Marshall, MI;
PDA J Pharm Sci Technol. 2023 Sep-Oct;77(5):376-401. doi: 10.5731/pdajpst.2022.012796. Epub 2023 Jun 15.
With machine learning (ML), we see the potential to better harness the intelligence and decision-making abilities of human inspectors performing manual visual inspection (MVI) and apply this to automated visual inspection (AVI) with the inherent improvements in throughput and consistency. This article is intended to capture current experience with this new technology and provides points to consider for successful application to AVI of injectable drug products. The technology is available today for such AVI applications. Machine vision companies have integrated ML as an additional visual inspection tool with minimal upgrades to existing hardware. Studies have demonstrated superior results in defect detection and reduction in false rejects, when compared with conventional inspection tools. ML implementation does not require modifications to current AVI qualification strategies. The utilization of this technology for AVI will accelerate recipe development by use of faster computers rather than by direct human configuration and coding of vision tools. By freezing the model developed with artificial intelligence tools and subjecting it to current validation strategies, assurance of reliable performance in the production environment can be achieved.
借助机器学习(ML),我们看到了更好地利用进行人工目视检查(MVI)的人工检查员的智能和决策能力,并将其应用于自动目视检查(AVI)的潜力,同时实现吞吐量和一致性方面的固有提升。本文旨在分享这项新技术的当前经验,并提供在注射用药品自动目视检查中成功应用的要点。如今这项技术已可用于此类自动目视检查应用。机器视觉公司已将机器学习作为一种额外的目视检查工具进行集成,只需对现有硬件进行最少的升级。与传统检查工具相比,研究已证明在缺陷检测和减少误判方面有更优异的结果。机器学习的实施无需对当前的自动目视检查验证策略进行修改。将这项技术用于自动目视检查将通过使用更快的计算机而非直接由人工配置和编写视觉工具代码来加速配方开发。通过冻结使用人工智能工具开发的模型并使其接受当前的验证策略,可以确保在生产环境中的可靠性能。